Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers

Prostate

Volumn 30, Issue 2, 1997, Pages 117-129

  Zhang, Ju ^a   Hess, Michael W ^b   Thurnher, Martin ^a   Hobisch, Alfred ^a   Radmayr, Christian ^a   Cronauer, Marcus V ^a   Hittmair, Anton ^b   Culig, Zoran ^a   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

cell culture; desmin; estradiol; human prostate; smooth muscle cells; smooth muscle myosin

Indexed keywords

ALPHA ACTIN; ANDROSTANOLONE; DESMIN; ESTRADIOL; HYDROCORTISONE; MYOSIN;

ARTICLE; CONTROLLED STUDY; CYSTECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROFILAMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; SMOOTH MUSCLE FIBER; URETHRA OBSTRUCTION;

ACTINS; ANDROGENS; BIOLOGICAL MARKERS; CELL ADHESION; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DESMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FIBROBLASTS; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, ELECTRON; MUSCLE, SMOOTH; MYOSINS; PROSTATE; TUMOR CELLS, CULTURED;

EID: 8044252155     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970201)30:2<117::AID-PROS7>3.0.CO;2-L     Document Type: Article

References (47)

1. Shapiro E, Hartanto V, Becich MJ, Lepor H: The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic BPH. J Urol 147:1293-1297, 1992.
2. Bartsch G, Brungger A, Schweikert U, Hintner H, Hopfl R, Rohr HP: Benign prostatic hyperplasia: A stromal disease. Urologe A 28:321-328, 1989.
3. Bartsch G, Brungger A, Schweikert U, Hintner H, Hopfl R, Rohr HP: Benign prostatic hyperplasia: Morphometric studies in relation to the hormone sensitivity of stromal tissue. Prog Clin Biol Res 386:51-65, 1994.
4. Deering RE, Bigler SA, King J, Choongkittaworn M, Aramburu E, Brawer MK: Morphometric quantitation of stroma in human benign prostatic hyperplasia. Urology 44:64-70, 1994
5. Bartsch G, Brüngger A, Schweikert HU, Hintner A, Stanzl U, Rohr HP: Benign prostatic hyperplasia: morphometric studies in relation to the pathogenesis. In (Schröder F, Ackermann R, eds): "Prostatic Hyperplasia." Berlin: Walter de Gryter & Co, 1989, pp 35-53.
6. Shapiro E, Hartanto V, Lepor H: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 147:1167-1170, 1992.
7. Habenicht UF, el Etreby MF, Lewis R, Ghoniem G, Roberts J: Induction of metachromasia in experimentally induced hyperplastic/hypertrophic changes in the prostate of the cynomolgus monkey (Macaca fascicularis). J Urol 142:1624-1626, 1989.
8. Robinette CL: Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 12:271-286, 1988.
9. Tam CC, Wong YC: Ultrastructural study of the effects of 17 beta-oestradiol on the lateral prostate and seminal vesicle of the castrated guinea pig. Acta Anat Basel 141: 51-62, 1991.
10. Morita T, Ando M, Kihara K, Matsumura T, Kamai T, Ohshima H: Subtypes of alpha 1-adrenoceptors in urinary bladder and urethral smooth muscle and prostatic J adenoma. Nippon Hinyokika Gakkai Zasshi 84:1629-1634, 1993.
11. Milroy E: Clinical overview of prazosin in the treatment of prostatic obstruction. Urol Int 45 (Suppl 1):1-3, 1990.
12. Lepor H: Alpha adrenergic antagonists for the treatment of symptomatic BPH. Int J Clin Pharmacol Ther Toxicol 27:151-155, 1989.
13. Lepor H: The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia. J Androl 12: 389-394, 1991.
14. Denis LJ: Future implications for the management of benign prostatic hyperplasia. Eur Urol 25 (Suppl 1):29-34, 1994.
15. Monda JM, Oesterling JE: Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin Proc 68:670-679, 1993.
16. Shapiro E, Hartanto V, Lepor H: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21:297-307, 1992.
17. Cunha GR: Mesenchymal-epithelial interactions during androgen-induced development of the prostate. In: (Lash JW and Saxon L, eds.), "Developmental Mechanisms: Normal and Abnormal". New York: A.R. Liss, 1985, pp. 15-24.
18. Cooke PS, Young P, Hess RA, Cunha GR: Estrogen receptor expression in developing epididymis, efferent ductules, and other male reproductive organs. Endocrinology 128:2874-2879, 1991.
19. Cooke PS, Young P, Cunha GR: Androgen receptor expression in developing male reproductive organs. Endocrinology 128:2867-2873, 1991.
20. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA: Normal and abnormal development of the male urogenital tract - Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 13:465-475, 1992.
21. Chung LWK, Cunha GR: Stromal epithelial interactions: II. Regulation of prostate growth by embryonic urogenical sinus mesenchyme. Prostate 4:503-511, 1983.
22. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 6:2123-2128, 1992.
23. Eicheler W, Tuohimaa P, Vilja P, Adermann K, Forssmann WG, Aumuller G: Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem 42:667-675, 1994.
24. Kirschenbaum A, Wang JP, Eliashvili E, Ren M, Levine AC, Russel DW: Immunohistochemical characterization of type II 5a-reductase expression in human fetal and adult prostates. J Urol 53:299A, 1995.
25. Horoszewicz JS, Leong SS, Ming Chu T, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog CHn Biol Res 37:115-132, 1980.
26. Gazdar AF, Carney DN, Russel EK, Sims HL, Baylin SB, Bunn PAJ, Guccion JG, Minna JD: Establishment of continuous clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 40:3502-3507, 1980.
27. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD: Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913-2923, 1985.
28. Hsu SM, Raine L, Fanger H: The use of avidin-biotinperoxidase complex (ABC) and unlabelled antibody PAP procedures. J Histochem Cytochem 29:577-580, 1981.
29. Skalli O, Ropraz P, Treciak A, Benzonana G, Gillessen D, Gabbiani G: A monoclonal antibody against α-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796, 1986.
30. Schneider MD, Sellers JR, Vahey M, Preston YA, Adelstein RS: Localization and topography of antigenic domains within the heavy chain of smooth muscle myosin. J Cell Biol 101:66-72, 1985.
31. Longtine JA, Pinkus GS, Fuhiwara K, Corson JM: Immunohistochemical localization of smooth muscle myosin in normal human tissues. J Histochem Cytochem 33:179-184, 1985.
32. Altmannsberger M, Osborn M, Schauer A, Weber K: Antibodies to different intermediate filament proteins. Cell type-specific markers on paraffin-embedded human tissue. Lab Invest 45:427-434, 1981.
33. Bohn W, Wiegers W, Beuttenmüller M, Traub P: Species-specific recognition patterns of monoclonal antibodies directed against vimentin. Exp Cell Res 201:1-7, 1992.
34. Franke WW, Schmid E, Osborne M, Weber K: Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci USA 75:5034-5038, 1978.
35. Esterre P, Melin M, Serrar M, Grimaud JA: New specific markers of human and mouse fibroblasts. Cell Mol Biol 38:297-301, 1992.
36. Kooistra A, Elissen NMJ, König JJ, Vermey M, van der Kwast TH, Romijn JC, Schröder FH: Immunocytochemical characterization of expiant cultures of human prostatic stromal cells. Prostate 27:42-49, 1995.
37. Ricciardelli C, Horsfall DJ, Skinner JM, Henderson DW, Marshall VR, Tilley WD: Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cell Dev Biol 25:1016-1024, 1989.
38. Wu YX, Kawabe K: Primary culture of smooth muscle cells from benign prostatic hyperplasia. J Smooth Muscle Res 30:51-56, 1994.
39. Ricciardelli C, Horsfall DJ, Sykes PJ, Marshall VR, Tilley WD: Effects of oestradiol-17 beta and 5 alpha-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression in vitro. J Endocrinol 140:373-383, 1994.
40. Kimura N, Mizokami A, Oonuma T, Sasano H, Nagura H: Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. J Histochem Cytochem 41:671-678, 1993.
41. Tilley WD, Horsfall DJ, Skinner JM, Henderson DW, Marshall VR: Effect of pubertal development on estrogen receptor levels and stromal morphology in the guinea pig prostate. Prostate 15:195-210, 1989.
42. West NB, Roselli CE, Resko JA, Greene GL, Brenner RM: Estrogen and progestin receptors and aromatase activity in rhesus monkey prostate. Endocrinology 123: 2312-2322, 1988.
43. Schulze H, Barrack ER: Immunocytochemical localization of estrogen receptors in the normal male and female canine urinary tract and prostate. Endocrinology 121:1773-1783, 1987.
44. Coffey DS, Isaacs JT: Control of prostate growth. J Urol 1:17-24, 1981.
45. Zhao GQ, Holterhus PM, Dammshauser I, Hoffbauer G, Aumuller G: Estrogen-induced morphological and immunohistochemical changes in stroma and epithelium of rat ventral prostate. Prostate 21:183-199, 1992.
46. Rohr HP, Naef HR, Holliger O, Oberholzer M, Ibach B, Weisbach L, Bartsch G: The effect of oestrogen on stromal growth of the dog prostate: A quantitative ultrastructural study. Urol Res 9:201-207, 1981.
47. Habenicht UF, el Etreby MF: Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies. J Androl 12:395-402, 1991.